KR910003098A - 주요 조직적합성 복합체 클래스 ⅰ항원과 특정 담체 분자와의 항원성 작제물, 이의 제조방법 및 용도 - Google Patents

주요 조직적합성 복합체 클래스 ⅰ항원과 특정 담체 분자와의 항원성 작제물, 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR910003098A
KR910003098A KR1019890010629A KR890010629A KR910003098A KR 910003098 A KR910003098 A KR 910003098A KR 1019890010629 A KR1019890010629 A KR 1019890010629A KR 890010629 A KR890010629 A KR 890010629A KR 910003098 A KR910003098 A KR 910003098A
Authority
KR
South Korea
Prior art keywords
antigenic construct
antigen
specific carrier
carrier molecule
class
Prior art date
Application number
KR1019890010629A
Other languages
English (en)
Other versions
KR970010760B1 (ko
Inventor
씨만 게르하르트
보스렛 클라우스
하랄트 세드라세크 한스
Original Assignee
필립 스타인, 헤리베르트 버그
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필립 스타인, 헤리베르트 버그, 베링베르케 아크티엔게젤샤프트 filed Critical 필립 스타인, 헤리베르트 버그
Publication of KR910003098A publication Critical patent/KR910003098A/ko
Application granted granted Critical
Publication of KR970010760B1 publication Critical patent/KR970010760B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음.

Description

주요 조직적합성 복합체 클래스 Ⅰ항원과 특정 담체 분자와의 항원성 작제물, 이의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 MHC클래스 Ⅰ분자와 특정담체와의 커플링 상태를 나타내는 것이다.
제2도는 플라스미드 백터 pUC19에 클로닝된 클론 54.1.24를 나타낸 것이다.
제3도는 클론 54.1.24의 분해 단편을 나타내는 것이다.

Claims (15)

  1. 주요 조직 적합성 복합체(MHC)클래스 Ⅰ항원이 C- 또는 N-말단부에서 특정 담체분자에 결합되어 있는 항원성 작제물.
  2. 주요 조직 적합성 복합체(MHC)클래스 Ⅰ항원이 아미노 말단부에서 특정 담체분자에 결합되어 있는 항원성 작제물.
  3. 주요 조직 적합성 복합체(MHC)클래스 Ⅰ항원이 C-말단부에서 특정 담체분자에 결합되어 있는 항원성 작제물.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 하나의 MHC클래스 Ⅰ항원이 각기 하나의 특정 담체 분자에 결합되어 있는 항원성 작제물.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 특정 담체 분자가 CD4도메인인 항원성 작제물.
  6. 제1항 내지 제4항 중 어느 한 항에 있어서, 특정 담체 분자가 모노클로날 항체인 항원성 작제물.
  7. 제6항에 있어서, 모노클로날 항체가 중쇄(heavy chain)의 일정한 부분에서 단축된 항원성 작제물.
  8. 제1항 내지 제7항중 어느 한 항에 있어서, MHC클래스 Ⅰ항원이 HLAB27W또는 HLAB27W인 항원성 작제물.
  9. 제1항 내지 제8항중 어느 한 항에 있어서, MHC클래스 Ⅰ항원이 담체 분자에 공유적으로 결합되어 잇는 항원성 작제물.
  10. 제1항 내지 제항중 어느 한 항에 있어서, MHC클래스 Ⅰ항원이 아비딘/비오틴을 통해 담체 분자에 결합되어 있는 항원성 작제물.
  11. 제1항 내지 제8항중 어느 한 항에 있어서, 항원성 작제물을 코드화하는 DNAs의 융합에 의한 유전자 조작에 따라 제조되는 항원성 작제물.
  12. 유전자의 필요한 부분을 이의 DNA 형태로 융합시키고, 적절한 조절 서열을 제공한 후, 적절한 발현 시스템에서 발현시킴을 특징으로 하여, 제1항 내지 제9항중 어느 한 항에서 청구한 항원성 작제물을 제조하는 방법.
  13. 표적 세포의 동형화를 위한 제1항 내지 제9항중 어느 한 항에서 청구한 항원성 작제물을 제조하는 방법.
  14. 제1항 내지 제11항중 어느 한 항에서 청구한 항원성 작제물을 함유하는 약제.
  15. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890010629A 1988-07-28 1989-07-27 주요 조직 적합성 복합체 제ⅰ형 항원과 담체 분자와의 항원성 작제물 KR970010760B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3825615A DE3825615A1 (de) 1988-07-28 1988-07-28 Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
DEP3825615.0 1988-07-28

Publications (2)

Publication Number Publication Date
KR910003098A true KR910003098A (ko) 1991-02-26
KR970010760B1 KR970010760B1 (ko) 1997-06-30

Family

ID=6359731

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890010629A KR970010760B1 (ko) 1988-07-28 1989-07-27 주요 조직 적합성 복합체 제ⅰ형 항원과 담체 분자와의 항원성 작제물

Country Status (12)

Country Link
US (2) US6548067B1 (ko)
EP (1) EP0352761B1 (ko)
JP (1) JP2812726B2 (ko)
KR (1) KR970010760B1 (ko)
AT (1) ATE128732T1 (ko)
AU (1) AU625065B2 (ko)
DE (2) DE3825615A1 (ko)
DK (1) DK371089A (ko)
ES (1) ES2080055T3 (ko)
FI (1) FI100973B (ko)
GR (1) GR3017915T3 (ko)
PT (1) PT91294B (ko)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
SE9002484L (sv) 1990-07-20 1992-01-21 Kabi Pharmacia Ab Nya substituerade polyetrar
US5885570A (en) * 1991-01-23 1999-03-23 The General Hospital Corporation Induction of tolerance with modified immunogens
JP3105629B2 (ja) † 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
DE4133791A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
US6030797A (en) * 1992-10-08 2000-02-29 Dade Behring Marburg Gmbh Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof
WO1997024446A2 (en) * 1995-12-29 1997-07-10 Chiron Corporation Gene delivery vehicle-targeting ligands
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
EP0920328A1 (en) * 1996-08-23 1999-06-09 Massachusetts Institute Of Technology Allogeneic histocompatibility complexes as mediators of cell destruction
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6248564B1 (en) * 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
AU2002301994B2 (en) * 1998-06-05 2008-05-15 Alexis Biotech Limited Method for producing cytotoxic T-cells
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20020051783A1 (en) * 1998-06-05 2002-05-02 Savage Philip Michael Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US6197591B1 (en) * 1998-09-14 2001-03-06 Pfizer Inc. Streptomyces avermitilis regulatory genes for increased avermectin production
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001072768A2 (en) * 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
AU5697001A (en) 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
AU5532601A (en) * 2000-04-12 2001-10-30 Univ Rochester Targeted vaccine delivery systems
EP1377609B1 (en) * 2001-03-14 2015-06-24 Dako Denmark A/S Mhc molecule constructs and their uses for diagnosis and therapy
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
JP5068931B2 (ja) * 2002-07-12 2012-11-07 ザ ジョンズ ホプキンス ユニバーシティー 独自のクローン形質のリンパ球受容体に結合する試薬および方法
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
WO2004087058A2 (en) * 2003-03-28 2004-10-14 Vaccinex, Inc. Targeted mhc class i alpha3 vaccine delivery systems
WO2005099361A2 (en) * 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
US20050287611A1 (en) * 2004-05-07 2005-12-29 Nugent C T Iv MHC bridging system for detecting CTL-mediated lysis of antigen presenting cells
EP1982176A1 (en) * 2006-01-30 2008-10-22 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
EA200870555A1 (ru) 2006-05-19 2009-04-28 Тева Фармасьютикал Индастриз, Лтд. Слитые белки, их применение и способы их получения
GB2442048B (en) * 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
CA2678618C (en) 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
AU2010203451B2 (en) 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
US20130011394A1 (en) * 2011-06-22 2013-01-10 Hoffmann-La Roche Inc. Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use
CA2887486A1 (en) * 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
JP6475167B2 (ja) 2012-12-21 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860875D1 (en) * 1977-09-28 1981-10-15 Nat Res Dev Immunological preparations incorporating mhc antigens and their production
DE3063736D1 (en) * 1979-03-27 1983-07-21 Nat Res Dev Improvements in or relating to immunological preparations
DE3531301A1 (de) * 1985-09-02 1987-03-05 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte glykoproteine, verfahren zu ihrer herstellung sowie ihre verwendung
DE3329184A1 (de) * 1983-08-12 1985-02-21 Behringwerke Ag, 3550 Marburg Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
DE3545576A1 (de) * 1985-11-28 1987-07-02 Behringwerke Ag Hla-b 27, dafuer codierende genomische dna und ihre verwendung
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0334300A1 (en) 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses

Also Published As

Publication number Publication date
EP0352761A2 (de) 1990-01-31
GR3017915T3 (en) 1996-01-31
US20040091488A1 (en) 2004-05-13
AU3900589A (en) 1990-02-01
FI100973B (fi) 1998-03-31
DK371089D0 (da) 1989-07-27
PT91294A (pt) 1990-02-08
EP0352761B1 (de) 1995-10-04
KR970010760B1 (ko) 1997-06-30
AU625065B2 (en) 1992-07-02
ATE128732T1 (de) 1995-10-15
EP0352761A3 (de) 1991-09-04
DK371089A (da) 1990-01-29
PT91294B (pt) 1995-03-01
US6548067B1 (en) 2003-04-15
FI893575A0 (fi) 1989-07-26
FI893575A (fi) 1990-01-29
ES2080055T3 (es) 1996-02-01
DE3825615A1 (de) 1990-02-01
DE58909458D1 (de) 1995-11-09
JPH02104599A (ja) 1990-04-17
JP2812726B2 (ja) 1998-10-22

Similar Documents

Publication Publication Date Title
KR910003098A (ko) 주요 조직적합성 복합체 클래스 ⅰ항원과 특정 담체 분자와의 항원성 작제물, 이의 제조방법 및 용도
Lu et al. Tutorial review. Oriented immobilization of antibodies and its applications in immunoassays and immunosensors
Onoue et al. Immunoglobulin M antibodies with ten combining sites
KR910001057A (ko) 이중특이성 및 올리고특이성 일가 및 올리고가 수용체. 이의 제조방법 및 이의 용도
NO20020491L (no) CTL4A-reseptor, fusjonsproteiner som inneholder den og anvendelser derav
KR900700606A (ko) Ig-cd4융합 단백질을 코드화하는 클론된 유전자 및 그의 이용
DK0613944T3 (da) Fremgangsmåder til regulering af immunresponset under anvendelse af CTLA4-bindende molekyler og IL4-bindende molekyler
CN103728447B (zh) 可控量子点位点特异性桥接偶联的抗体标记方法及其应用
Fong et al. Affinity separation using an Fv antibody fragment–“smart” polymer conjugate
Pepe The myosin filament: immunochemical and ultrastructural approaches to molecular organization
JP3536731B2 (ja) ＨＩＶ−１ｐ２４抗原の免疫測定方法及び試薬
Furie et al. Antibodies to the unfolded form of a helix-rich region in staphylococcal nuclease
Lobner et al. Getting CD19 into shape: expression of natively folded “difficult-to-express” CD19 for staining and stimulation of CAR-T cells
Hytönen et al. Dual‐affinity avidin molecules
KR970048455A (ko) 매독 트레포네마 융합 항원 및 그 융합 항원을 사용한 항매독 트레포네마 항체의 측정 방법
Vest Hansen et al. Phage display of peptide/major histocompatibility class I complexes
Baumann et al. Indirect immobilization of recombinant proteins to a solid phase using the albumin binding domain of streptococcal protein G and immobilized albumin
NO174153C (no) Antigen og monoklonalt antistoff for anvendelse in vitro, samt immunologiske reagenser inneholdende disse
Lénon et al. A useful epitope tag derived from maltose binding protein
Yu et al. Fc-specific and covalent conjugation of a fluorescent protein to a native antibody through a photoconjugation strategy for fabrication of a novel photostable fluorescent antibody
Thompson et al. Identification, production, and use of polyol-responsive monoclonal antibodies for immunoaffinity chromatography
Evan A simple and rapid solid phase enzyme-linked immunoadsorbence assay for screening monoclonal antibodies to poorly soluble proteins
TWI593967B (zh) 二級抗體所辨識之抗原決定位及其用途
Zhou et al. High‐Affinity Antibody Detection with a Bivalent Circularized Peptide Containing Antibody‐Binding Domains
Grattone et al. Co‐operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine‐transfected fibroblasts

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee